AgomAb Therapeutics (NASDAQ:AGMB) Stock: Insider Tim Jasper Knotnerus Buys 6,000 Shares

Posted by Geri Gentry on Oct 9th, 2026

AgomAb Therapeutics NV (NASDAQ:AGMB – Get Free Report) CEO Tim Jasper Knotnerus acquired 6,000 shares of the firm’s stock in a transaction dated Monday, October 5th. The stock was bought at an average cost of $8.48 per share, for a total transaction of $50,880.00. Following the purchase, the chief executive officer directly owned 16,823 shares of the company’s stock, valued at approximately $142,659.04. This trade represents a 55.44% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Tim Jasper Knotnerus also recently made the following trade(s):

On Tuesday, October 6th, Tim Jasper Knotnerus acquired 5,000 shares of AgomAb Therapeutics stock. The shares were bought at an average cost of $8.70 per share, for a total transaction of $43,500.00.

AgomAb Therapeutics Trading Up 4.8%

Shares of NASDAQ:AGMB opened at $9.22 on Friday. The stock has a 50 day moving average of $12.68 and a 200 day moving average of $11.95. AgomAb Therapeutics NV has a 12-month low of $7.97 and a 12-month high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. As a group, research analysts expect that AgomAb Therapeutics NV will post -1.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a report on Wednesday, September 16th. B. Riley Financial began coverage on AgomAb Therapeutics in a report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target on the stock. Wall Street Zen downgraded AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. Piper Sandler initiated coverage on AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an “overweight” rating for the company. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, AgomAb Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $37.50.

Check Out Our Latest Stock Analysis on AGMB

Trending Headlines about AgomAb Therapeutics

Here are the key news stories impacting AgomAb Therapeutics this week:

Positive Sentiment: CEO Tim Jasper Knotnerus purchased 11,000 shares across October 5–6 for approximately $94,380, increasing his ownership substantially. CFO Pierre Kemula also bought 10,000 shares for about $85,900, while director David Epstein acquired 5,000 shares for $43,500. The coordinated insider buying may be viewed as a signal of management and board confidence in AgomAb’s long-term prospects. Insider Buying: AgomAb Therapeutics CEO Purchases Shares
Positive Sentiment: AgomAb plans to present STENOVA open-label extension data for ontunisertib at UEG Week 2026 and host a scientific symposium focused on fibro-inflammation. The event could provide investors with additional information on the drug’s durability, safety and potential in inflammatory diseases. AgomAb UEG Week 2026 Presentation
Neutral Sentiment: The planned presentation is a potential near-term catalyst, but the announcement did not include the actual clinical results. Investors will likely await the data before reassessing the program’s prospects.
Negative Sentiment: AgomAb remains a clinical-stage biotechnology company reporting quarterly losses, with analysts expecting a full-year loss of approximately $1.76 per share. Shares are also trading below their 50-day and 200-day moving averages, reflecting continued volatility and execution risk.

AgomAb Therapeutics Company Profile

(Get Free Report)

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.